CyteType Pioneer
Partner Program

Five partner slots. A full CyteType run against your existing cell-type annotation pipeline. No cost, full evidence trail.

Apply Now

Applications close 15 May 2026

Cell-type annotation remains one of the slowest and least documented steps in single-cell workflows. Labels vary across analysts, rationale goes unrecorded, and downstream decisions in target selection and biomarker strategy inherit that uncertainty. Reproducibility suffers, and reviews stall on questions no one can answer after the fact. CyteType was built to fix this.

Current workflow vs. CyteType

Where the programme shifts the economics of annotation.

	Current workflow	With CyteType
Speed	Weeks of manual curation	Hours, fully automated
Consistency	Varies by analyst	Reproducible across runs
Documentation	Labels only, no rationale	Full audit trail per cluster
Evidence	Scattered, unlinked	PubMed-linked, scored

Therapeutic areas in this cohort

We've selected these three therapeutic areas for the first Pioneer Partner cohort.

Cluster 6 Final annotation: Progenitor Exhausted CD8+ T Cell (Tpex)

Tpex Marker concordance 92%
Term. exhausted CD8+ TCF7+, no HAVCR2 or ENTPD1
Central memory CD8+ TOX+, PDCD1 high rules out Tcm
CD8+ effector No GZMB, PRF1 signature

Cluster 8 Final annotation: Disease-Associated Microglia (DAM)

DAM Marker concordance 91%
Activated microglia Lacks SPP1, LPL signature
Homeostatic microglia P2RY12, TMEM119 downregulated
BAM No MRC1, LYVE1 expression

Cluster 12 Final annotation: Peripheral T Helper Cell (Tph)

Tph Marker concordance 89%
Tfh CXCR5 negative, no BCL6
Th1 No TBX21, IFNG signature
Treg FOXP3-, IL2RA absent

Learn more about CyteType

Head-to-head benchmark

500 clusters, cluster-by-cluster comparison against your existing pipeline.

Interactive evidence report

Confidence scores, pathway enrichment, Cell Ontology IDs, PubMed-linked trail.

Scientific debrief

60-min session with the Nygen CEO and science team.

Pioneer Partner status

Dedicated support, priority access to upcoming releases.

Pioneer pricing

50% off published rates for 12 months post-program, plus a 3-month extended trial.

How it works

Apply

Download and complete the application form and email it before 15 May 2026.
Selection and NDA

Applications are reviewed against scientific fit, dataset quality, and research impact. Selected partners receive a mutual NDA for execution before any data is shared.
Data submission

Provide a clustered AnnData or Seurat object within 2 weeks of selection.
CyteType run

Nygen runs CyteType on your dataset and generates the full comparison report.
Report and debrief

You receive the interactive evidence report and a 60-minute scientific debrief with the Nygen team.

What we ask

A light lift from your side, with clear deadlines.

Submit an application by 15 May 2026.
Provide a clustered AnnData or Seurat object within 2 weeks of selection.
Participate in a 60-minute debrief within 3 weeks of receiving results.
Share written feedback on annotation quality and its impact within 2 weeks of debrief. Nygen may reference this publicly.

Your data stays yours

ISO 27001 grade

Security controls aligned with ISO 27001 across storage, access, and processing.

DPA secured

A Data Processing Agreement is executed before any transfer.

No training on data

Your data is never used to train, fine-tune, or improve any model.

Delete on request

Full deletion on request at any point, with confirmation.

All processing runs under strict security and privacy controls. You retain all IP for your data and any discoveries made as part of the Pioneer Programme.